SCHEMBL3140080

SCHEMBL3140080

O=C(C(=O)N1CCC[C@H]1C(=O)O)C1CCCCC1

nearest known ligand 0.53

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
FKBP1A P62942 3/20 0.51
ACE P12821 5/20 0.46
CES2 O00748 1/20 0.45
CES1 P23141 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14407783 1.00 FKBP1A (0.51) FKBP1AACECES2CES1
SCHEMBL3397276 1.00 FKBP1A (0.51) FKBP1AACECES2CES1
SCHEMBL5834349 1.00 FKBP1A (0.51) FKBP1AACECES2CES1
SCHEMBL14394666 0.98 FKBP1A (0.49) FKBP1AACE
SCHEMBL5966183 0.96 FKBP1A (0.55) FKBP1AACECES2CES1
SCHEMBL14407780 0.96 FKBP1A (0.55) FKBP1AACECES2CES1
SCHEMBL14407787 0.96 FKBP1A (0.55) FKBP1AACECES2CES1
SCHEMBL14407782 0.96 FKBP1A (0.55) FKBP1AACECES2CES1
SCHEMBL14407795 0.96 FKBP1A (0.55) FKBP1AACECES2CES1
SCHEMBL14407789 0.95 FKBP1A (0.52) FKBP1AACE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100330063-A1 STEM-LIKE CELLS, METHOD FOR DE-DIFFERENTIATING MAMMALIAN SOMATIC CELLS INTO STEM-LIKE CELLS, AND METHOD FOR DIFFERENTIATING STEM-LIKE CELLS GLIAMED, INC. (US) 2010-12-30 US claimed
US-20080076817-A1 Small Molecule Rotamase Enzyme Inhibitors HAMILTON GREGORY S 2008-03-27 US claimed
US-7282510-B2 Small molecule inhibitors of rotamase enzyme activity GLIAMED, INC. (US) 2007-10-16 US claimed
EP-1227859-B1 NEUROPHILIN LIGANDS FOR TREATING OCULAR CONDITIONS ALCON INC (CH) 2006-08-09 EP claimed
US-20050272780-A1 Small molecule inhibitors of rotamase enzyme activity GUILFORD NIL HOLDINGS, INC. 2005-12-08 US claimed
US-6943187-B2 Pyrrolidine derivative hair growth compositions and uses GPI NIL HOLDINGS, INC. (US) 2005-09-13 US claimed
US-20040186098-A1 Method for preventing and treating hearing loss using sensorineurotrophic compounds AMGEN INC. 2004-09-23 US claimed
US-20040049046-A1 Small molecule inhibitors of rotamase enzyme activity GPI NIL HOLDINGS, INC. (US) 2004-03-11 US claimed
US-20030203890-A1 Method for treating nerve injury caused as a result of surgery NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2003-10-30 US claimed
US-20020198250-A1 Pyrrolidine derivative hair growth compositions and uses GLIAMED, INC. 2002-12-26 US claimed
EP-0769006-B1 SMALL MOLECULE INHIBITORS OF ROTAMASE ENZYME ACTIVITY GUILFORD PHARM INC (US) 2000-11-08 EP claimed
EP-0998263-A1 PYRROLIDINE DERIVATIVE HAIR GROWTH COMPOSITIONS AND USES GUILFORD PHARMACEUTICALS INC. (US) 2000-05-10 EP claimed
EP-0992492-A1 Small molecule inhibitors of rotamase enzyme activity GUILFORD PHARMACEUTICALS INC. (US) 2000-04-12 EP claimed
US-5859031-A Small molecule inhibitors of rotamase enzyme activity GPI NIL HOLDINGS, INC. (US) 1999-01-12 US claimed
WO-1998055091-A1 PYRROLIDINE DERIVATIVE HAIR GROWTH COMPOSITIONS AND USES GUILFORD PHARMACEUTICALS INC. (US) 1998-12-10 WO claimed
EP-0769006-A4 GUILFORD PHARM INC (US) 1997-05-28 EP claimed
EP-0769006-A1 SMALL MOLECULE INHIBITORS OF ROTAMASE ENZYME ACTIVITY GUILFORD PHARMACEUTICALS INC. (US) 1997-04-23 EP claimed
US-5614547-A Small molecule inhibitors of rotamase enzyme GUILFORD PHARMACEUTICALS INC. (US) 1997-03-25 US claimed
WO-1996040633-A9 SMALL MOLECULE INHIBITORS OF ROTAMASE ENZYME ACTIVITY 1997-02-27 WO claimed
WO-1996040633-A1 SMALL MOLECULE INHIBITORS OF ROTAMASE ENZYME ACTIVITY GUILFORD PHARMACEUTICALS INC. (US) 1996-12-19 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186098-A1 Method for preventing and treating hearing loss using sensorineurotrophic compounds GAP43, CHAT, MYOC FKBP1A 2845/4885ACE 2889/4885CES2 2098/4885
US-20030203890-A1 Method for treating nerve injury caused as a result of surgery NGF, BDNF, GAP43 FKBP1A 1167/4885ACE 1092/4885CES2 933/4885
US-20040049046-A1 Small molecule inhibitors of rotamase enzyme activity FKBP8, FKBP14, PREP FKBP1A 4/4885ACE 371/4885CES2 1432/4885
US-20050272780-A1 Small molecule inhibitors of rotamase enzyme activity FKBP8, FKBP1A, PREP FKBP1A 2/4885ACE 339/4885CES2 1170/4885
US-20100330063-A1 STEM-LIKE CELLS, METHOD FOR DE-DIFFERENTIATING MAMMALIAN SOMATIC CELLS INTO STEM-LIKE CELLS, AND METHOD FOR DIFFERENTIATING STEM-LIKE CELLS POU2F1, POU2F2, POU5F1 FKBP1A 4746/4885ACE 4534/4885CES2 2057/4885
US-20020198250-A1 Pyrrolidine derivative hair growth compositions and uses MKI67, PLOD2, HDGF FKBP1A 42/4885ACE 2839/4885CES2 4030/4885
US-20080076817-A1 Small Molecule Rotamase Enzyme Inhibitors FKBP8, FKBP1A, FKBP2 FKBP1A 2/4885ACE 636/4885CES2 2010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.